UK Flow Cytometry Market Size & Outlook, 2023-2030
UK flow cytometry market, 2018-2030 (US$M)
Related Markets
UK flow cytometry market highlights
- The UK flow cytometry market generated a revenue of USD 237.8 million in 2023 and is expected to reach USD 403.0 million by 2030.
- The UK market is expected to grow at a CAGR of 7.8% from 2024 to 2030.
- In terms of segment, instruments was the largest revenue generating product in 2023.
- Software is the most lucrative product segment registering the fastest growth during the forecast period.
Flow cytometry market data book summary
| Market revenue in 2023 | USD 237.8 million |
| Market revenue in 2030 | USD 403.0 million |
| Growth rate | 7.8% (CAGR from 2023 to 2030) |
| Largest segment | Instruments |
| Fastest growing segment | Software |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Instruments, Reagents & Consumables, Software, Accessories, Services |
| Key market players worldwide | Danaher Corp, BD, Sysmex Corp, Agilent Technologies, Apogee Enterprises Inc, Bio-Rad Laboratories Inc Class A, Thermo Fisher Scientific Inc, Wipro Ltd ADR, Diasorin SpA, Miltenyi Biotec, Sony Group Corp |
Other key industry trends
- In terms of revenue, UK accounted for 5.5% of the global flow cytometry market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, Germany flow cytometry market is projected to lead the regional market in terms of revenue in 2030.
- UK is the fastest growing regional market in Europe and is projected to reach USD 403.0 million by 2030.
Instruments was the largest segment with a revenue share of 35.53% in 2023. Horizon Databook has segmented the UK flow cytometry market based on instruments, reagents & consumables, software, accessories, services covering the revenue growth of each sub-segment from 2018 to 2030.
According to GLOBOCAN, in 2020, around 457,960 new cases of cancer were diagnosed in the UK, accounting for around 179,648 deaths. Moreover, according to Diabetes UK, in 2019, 3.9 million people were suffering from diabetes in the country.
The high prevalence of chronic diseases and rising geriatric population are some of the factors propelling the demand for flow cytometry for clinical applications. In addition, increase in R&D activities for the development of COVID-19 biological therapies and vaccines in the UK is anticipated to boost the demand for flow cytometry solutions for research purposes.
For instance, in June 2020, namilumab (IZN-101)—an investigational therapy by UK-based Izana Bioscience has been chosen as the potential treatment to be tested in a new major UK drug trial for hospitalized COVID-19 patients.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Flow Cytometry Market Scope
Flow Cytometry Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
UK flow cytometry market size, by product, 2018-2030 (US$M)
UK Flow Cytometry Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
